Associated Papers
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.
Piha-Paul SA et al.
Npj Precision Oncology, 2024
39085400 (PubMed )
Supplement: 41698_2024_634_MOESM1_ESM.pdf
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E et al.
Bmc Cancer, 2016
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
Prevalence of BRCA1 founder mutations in western Poland.
Jasinska A et al.
Human Mutation, 2001
High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
Grzybowska E et al.
Human Mutation, 2000
Select a paper to view details